Market By Drug Class, Distribution Channel, End-user, And Geography | Forecast 2019-2028
Triton’s research on the Europe immunosuppressants drugs market depicts that it will grow at a stable pace with a CAGR of 3.88% in terms of revenue during the forecast period 2019-2028.
Report scope can be customized per your requirements. Request For Customization
The countries evaluated in this market include:
• The UK
• Germany
• France
• Spain
• Italy
• Russia
• Rest of Europe
Over 80 different types of autoimmune diseases are prevalent in the United Kingdom, affecting more than 4 million people. While advancements in technology have enabled the formulation of treatments to reduce autoimmune attacks, these diseases still have no cure. Existing drugs may not show effectiveness when given to all patients, and may even result in side-effects. It is necessary to have a better knowledge of how these diseases develop, so as to develop better treatments.
In the past couple of years, many investigations involving the genetics of autoimmunity have discovered a common feature - a particular gene named TYK2. This gene is also associated with multiple other autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, and type 1 diabetes. After discovering this gene, a drug targeting TYK2 was developed, and it seems promising for the treatment of psoriasis. In fact, looking at the positive results, this drug generates hope for the treatment of other autoimmunity-related conditions as well. However, these are future developments, and, till then, immunosuppressants drugs will be in huge demand for the treatment of autoimmune diseases.
In France, all citizens automatically become organ donors, unless they decide to opt-out. This comes after the amendment in laws pertaining to organ donation. This law is now in line with similar laws enacted in Austria and Spain, where there is “presumed consent.” This means, every person is eligible for donating organs and tissues after death, unless they specifically decide not to. Thus, there is a huge demand for organ transplantation in the country. The growing demand for organ transplantation implies an increase in the demand for immunosuppressant drugs. This is helping the growth of the immunosuppressant drugs market in the country over the forecasted period.
Allergan (acquired by AbbVie Inc), is a global specialty pharma company focused on developing, manufacturing, selling, marketing, and distributing pharmaceutical products, medical aesthetics, biosimilars and OTC pharmaceutical products. Restasis and Restasis MultidoseTM are the immunosuppressant drugs manufactured by the company. It is headquartered in Dublin, Ireland.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE IMMUNOSUPPRESSANT DRUGS MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1. ORGAN TRANSPLANTATION LEADS THE MARKET BY END-USER
2.2.2. PHARMACEUTICAL INDUSTRY SHOWING GROWTH TRENDS
2.2.3. IMPACT OF COVID-19 ON TRANSPLANT RECIPIENTS
2.3. EVOLUTION & TRANSITION OF IMMUNOSUPPRESSANT DRUGS
2.4. PORTER’S FIVE FORCE ANALYSIS
2.4.1. THREAT OF NEW ENTRANTS
2.4.2. THREAT OF SUBSTITUTE
2.4.3. BARGAINING POWER OF SUPPLIERS
2.4.4. BARGAINING POWER OF BUYERS
2.4.5. THREAT OF COMPETITIVE RIVALRY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. MARKET DRIVERS
2.7.1. DEMAND FROM ORGAN TRANSPLANTATION
2.7.2. RISE IN THE NUMBER OF AUTOIMMUNE DISORDERS
2.8. MARKET RESTRAINTS
2.8.1. SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
2.9. MARKET OPPORTUNITIES
2.9.1. DEMAND FROM EMERGING ECONOMIES
2.9.2. EXPORTS OF DRUGS AND MEDICINE WORLDWIDE ON RISE
2.10. MARKET CHALLENGES
2.10.1. LACK OF AWARENESS ABOUT ORGAN DONATION
3. EUROPE IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK – BY DRUG CLASS
3.1. CORTICOSTEROIDS
3.2. MONOCLONAL ANTIBODIES
3.3. CALCINEURIN INHIBITORS
3.4. MTOR INHIBITORS
3.5. OTHERS
4. EUROPE IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK - BY DISTRIBUTION CHANNEL
4.1. HOSPITAL PHARMACIES
4.2. RETAIL PHARMACIES
4.3. ONLINE PHARMACIES
5. EUROPE IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK - BY END-USER
5.1. ORGAN TRANSPLANTATION
5.2. AUTOIMMUNE DISORDERS
5.3. OTHERS
6. EUROPE IMMUNOSUPPRESSANT DRUGS MARKET – REGIONAL OUTLOOK
6.1. UNITED KINGDOM
6.2. GERMANY
6.3. FRANCE
6.4. SPAIN
6.5. ITALY
6.6. RUSSIA
6.7. REST OF EUROPE
7. COMPETITIVE LANDSCAPE
7.1. ABBVIE INC
7.2. ALLERGAN (ACQUIRED BY ABBVIE INC)
7.3. ASTELLAS PHARMA INC
7.4. BRISTOL-MYERS SQUIBB COMPANY
7.5. CIPLA LTD
7.6. DR REDDYS LABORATORIES LTD
7.7. F HOFFMANN-LA ROCHE LTD
7.8. GLAXOSMITHKLINE PLC
7.9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE)
7.10. JANSSEN PHARMACEUTICALS INC (JOHNSON & JOHNSON SERVICES INC)
7.11. MYLAN NV
7.12. NOVARTIS AG
7.13. PFIZER INC
7.14. SANOFI
7.15. VELOXIS PHARMACEUTICALS INC
8. METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY
TABLE 1: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS INDEX
TABLE 3: VENDOR SCORECARD
TABLE 4: SIDE-EFFECTS OF IMMUNOSUPPRESSANT DRUGS
TABLE 5: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
TABLE 6: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2019-2028 (IN $ MILLION)
TABLE 7: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (IN $ MILLION)
TABLE 8: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
FIGURE 1: EVOLUTION & TRANSITION OF IMMUNOSUPPRESSANT DRUGS
FIGURE 2: PORTER’S FIVE FORCE ANALYSIS
FIGURE 3: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY CORTICOSTEROIDS, 2019-2028 (IN $ MILLION)
FIGURE 4: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
FIGURE 5: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY CALCINEURIN INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 6: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 7: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 8: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 9: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 10: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY ONLINE PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 11: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TRANSPLANTATION, 2019-2028 (IN $ MILLION)
FIGURE 12: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY AUTOIMMUNE DISORDERS, 2019-2028 (IN $ MILLION)
FIGURE 13: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 14: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 15: UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 16: GERMANY IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 17: FRANCE IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 18: SPAIN IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 19: ITALY IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 20: RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 21: REST OF EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)